WO2006075020A3 - Ampa antagonist for the treatment of dizziness, including vertigo and meniere's disorder - Google Patents

Ampa antagonist for the treatment of dizziness, including vertigo and meniere's disorder Download PDF

Info

Publication number
WO2006075020A3
WO2006075020A3 PCT/EP2006/050194 EP2006050194W WO2006075020A3 WO 2006075020 A3 WO2006075020 A3 WO 2006075020A3 EP 2006050194 W EP2006050194 W EP 2006050194W WO 2006075020 A3 WO2006075020 A3 WO 2006075020A3
Authority
WO
WIPO (PCT)
Prior art keywords
meniere
dizziness
disorder
treatment
including vertigo
Prior art date
Application number
PCT/EP2006/050194
Other languages
French (fr)
Other versions
WO2006075020A2 (en
Inventor
Lechoslaw A Turski
Vliet Bernard J Van
Rene Remie
Der Heijden Johannes A M Van
Martinus Th M Tulp
Original Assignee
Solvay Pharm Bv
Lechoslaw A Turski
Vliet Bernard J Van
Rene Remie
Der Heijden Johannes A M Van
Martinus Th M Tulp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv, Lechoslaw A Turski, Vliet Bernard J Van, Rene Remie, Der Heijden Johannes A M Van, Martinus Th M Tulp filed Critical Solvay Pharm Bv
Publication of WO2006075020A2 publication Critical patent/WO2006075020A2/en
Publication of WO2006075020A3 publication Critical patent/WO2006075020A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of 8,9-dimethyl-5-phenyl-11 H-1 ,3-dioxolo[4,5-h]-imidazo[1 ,2-c][2,3]benzodiazepine: tautomers and N-oxides thereof, as well as pharmacologically acceptable salts, hydrates and solvates of this compound and its tautomers and N-oxides, for the preparation of a pharmaceutical composition for the treatment, amelioration or prevention of dizziness, including vertigo and Meniere's disorder.
PCT/EP2006/050194 2005-01-14 2006-01-13 Ampa antagonist for the treatment of dizziness, including vertigo and meniere's disorder WO2006075020A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64359805P 2005-01-14 2005-01-14
EP05100205 2005-01-14
EP05100205.3 2005-01-14
US60/643,598 2005-01-14

Publications (2)

Publication Number Publication Date
WO2006075020A2 WO2006075020A2 (en) 2006-07-20
WO2006075020A3 true WO2006075020A3 (en) 2007-03-08

Family

ID=35789175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/050194 WO2006075020A2 (en) 2005-01-14 2006-01-13 Ampa antagonist for the treatment of dizziness, including vertigo and meniere's disorder

Country Status (1)

Country Link
WO (1) WO2006075020A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076590A2 (en) * 2000-04-05 2001-10-18 Mimicking Man Manually, Inc. Treatment for benign positional vertigo using antiepileptics
US20040010525A1 (en) * 2002-07-10 2004-01-15 Bennett Forrest H. Method and apparatus for molecular mechanics analysis of molecular systems
US20040077618A1 (en) * 2002-10-22 2004-04-22 Bennani Youssef L. Cycloalkylamides and their therapeutic applications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076590A2 (en) * 2000-04-05 2001-10-18 Mimicking Man Manually, Inc. Treatment for benign positional vertigo using antiepileptics
US20040010525A1 (en) * 2002-07-10 2004-01-15 Bennett Forrest H. Method and apparatus for molecular mechanics analysis of molecular systems
US20040077618A1 (en) * 2002-10-22 2004-04-22 Bennani Youssef L. Cycloalkylamides and their therapeutic applications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEGHI E ET AL: "Basic and clinical research on amyotrophic lateral sclerosis and other motor neuron disorders in Italy: Recent findings and achievements from a network of laboratories", NEUROLOGICAL SCIENCES 2004 ITALY, vol. 25, no. SUPPL. 2, 2004, pages S41 - S60, XP008072203, ISSN: 1590-1874 *
ELGER, BERND ET AL: "Novel .alpha.-Amino-3-hydroxy-5-methyl-4-isoxazole Propionate (AMPA) Receptor Antagonists of 2,3-Benzodiazepine Type: Chemical Synthesis, in Vitro Characterization, and in Vivo Prevention of Acute Neurodegeneration", JOURNAL OF MEDICINAL CHEMISTRY , 48(14), 4618-4627 CODEN: JMCMAR; ISSN: 0022-2623, 2005, XP008072192 *

Also Published As

Publication number Publication date
WO2006075020A2 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
WO2002044183A3 (en) Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
HK1105979A1 (en) Pyrrolo [3,2-c] pyridine derivatives and processes for the preparation
WO2006011050A3 (en) Pyridine derivatives
WO2006029146A3 (en) 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
EP1670466A4 (en) Preparation of 1, 6, 7- trisubstituted azabenzimidazoles as kinase inhibitors
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2005082883A3 (en) Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
WO2005082893A3 (en) Histamine h3 receptor antagonists, preparation and therapeutic uses
MX2010007746A (en) 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses.
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
MX2007006387A (en) 3-substituted pyridine derivatives as h3 antagonists.
WO2008077557A8 (en) 8-ethinylxanthine derivatives as selective a2a receptor antagonists
WO2005037197A3 (en) Preperation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors
WO2007100610A3 (en) Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators
WO2008070313A3 (en) 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
PT1784402E (en) Pyrrolo[3,2-c]pyridine derivatives and processes for the preparation thereof
WO2005079766A3 (en) Therapeutic combination comprising a tissue factor antagonist and anti-cancer compounds
WO2002051983A3 (en) Novel compounds and compositions as cathepsin inhibitors
WO2007066337A3 (en) Jasmonate derivatives, pharmaceutical compositions and methods of use thereof
WO2003057145A3 (en) SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
WO2008026156A3 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
WO2004094431A3 (en) 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists
JO2550B1 (en) Pyrido [2,3-d] pyrimidine derivatives, preperation thereof, Therapeutic use thereof
WO2005107752A3 (en) Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06701276

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6701276

Country of ref document: EP